RudaCure (CEO Yongho Kim), a company specializing in sensory disorder treatment development, announced on the 21st that it has been selected for the Ministry of SMEs and Startups' 'Scale-up TIPS' program, recognized for its non-narcotic analgesic development capabilities through ion channel modulation.
'Scale-up TIPS' is a government private investment-led R&D support program that enables promising technology-based SMEs and ventures to boldly pursue high-risk, innovative R&D. When a private operator invests KRW 1 billion or more, the government provides up to KRW 2 billion for investment-type R&D and up to KRW 1.2 billion over 3 years for investment-linked R&D.
Through this program, RudaCure plans to receive a total of KRW 1.2 billion in support over the next 3 years to accelerate the commercialization of its non-narcotic analgesic RCI002 project.
The compound discovered by RudaCure simultaneously acts on both the ion channel TRPV1 and MOR (Mu-Opioid Receptor). This is a differentiated non-narcotic analgesic approach that overcomes the addiction and tolerance issues of existing MOR-targeting narcotic analgesics while addressing the body temperature elevation side effects associated with TRPV1 channel modulation.
RudaCure stated, "Through this Scale-up TIPS selection, we have established a foundation for accelerating the commercialization of the RCI002 project. We will do our best to lead the next-generation non-narcotic analgesic market based on our ion channel modulation technology."